Apple Inc. (NASDAQ:AAPL) did have a big success in California when jurors awarded it about $930 million after a 2012 trial, but the company failed to persuade the judge to ban the sale of Samsung phones in the United States because of the infringement. A US appeals court has refused to revive a Samsung Electronics patent case against Apple, affirming a decision in favour of the iPhone and iPad maker. Apple Inc. (NASDAQ:AAPL) net profit margin is 21.40% and weekly performance is 0.82%. On last trading day company shares ended up $593.87. Analysts mean target price for the company is $626.93. Apple Inc. (NASDAQ:AAPL) distance from 50-day simple moving average (SMA50) is 9.07%.
Elite Pharmaceuticals Inc (OTCBB:ELTP)has announced the issuance of US Patent No. 8,703,186 titled ‘Abuse-Resistant Oral Dosage Forms and Method of Use Thereof’. This patent expands the intellectual property for the Company’s opioid abuse deterrent technology. Elite now has three US patents and one Canadian patent issued in this area with additional patents pending in the US, Canada and Europe. Elite president and CEO Nasrat Hakim noted that the company is pleased with this additional patent coverage. Elite Pharmaceuticals Inc (OTCBB:ELTP) shares advanced 13.41% in last trading session and ended the day on $0.465 .
InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV) announced that a second clinical site in its clinical study, the Carolinas Medical Center in Charlotte, NC, is now open for enrollment for patients with acute spinal cord injury (SCI). Dom Coric, MD, of Carolina Neurosurgery & Spine Associates, Chief of Neurosurgery at Carolinas Medical Center, is a Co-Principal Investigator. William L. Bockenek, MD, Chief Medical Officer of Carolinas Rehabilitation, part of the Carolinas HealthCare System, and Chairman of the Department of Physical Medicine and Rehabilitation at Carolinas Medical Center, is also a Co-Principal Investigator. Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) shares moved up 0.85% in last trading session and was closed at $1.19 , while trading in range of $1.17 – $1.20.
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced that John C. Houghton, President and Chief Executive Officer, will present at the Third Annual Marcum MicroCap Conference in New York on Thursday, May 29, 2014 at 3:30 p.m. EDT. Nephros, Inc. (OTCBB:NEPH) ended the last trading day at $0.750 .
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, reported financial results for its fiscal third quarter ended March 31, 2014. Third quarter fiscal year 2014 revenue totaled $3.4 million, down 12% sequentially and down 18% compared to the third quarter of fiscal year 2013. The revenue declines sequentially and compared to the third quarter of fiscal year 2013 were due to lower volume of units sold in both product lines. Urologix Inc (OTCMKTS:ULGX) On last trading day company shares ended up $0.170.